Combination of FDG PET/CT and Contrast-Enhanced MSCT in Detecting Lymph Node Metastasis of Esophageal Cancer

  • Tan, Ru (Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong University) ;
  • Yao, Shu-Zhan (Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong University) ;
  • Huang, Zhao-Qin (Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong University) ;
  • Li, Jun (Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong University) ;
  • Li, Xin (Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong University) ;
  • Tan, Hai-Hua (Department of Hematology, The Central Hospital of TaiAn) ;
  • Liu, Qing-Wei (Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong University)
  • 발행 : 2014.10.11


Background: Lymph node metastasis is believed to be a dependent negative prognostic factor of esophageal cancer. To explore detection methods with high sensitivity and accuracy for metastases to regional and distant lymph nodes in the clinic is of great significance. This study focused on clinical application of FDG PET/CT and contrast-enhanced multiple-slice helical computed tomography (MSCT) in lymph node staging of esophageal cancer. Materials and Methods: One hundred and fifteen cases were examined with enhanced 64-slice-MSCT scan, and FDG PET/CT imaging was conducted for neck, chest and upper abdomen within one week. The primary lesion, location and numbers of metastatic lymph nodes were observed. Surgery was performed within one week after FDG PET/CT detection. All resected lesions were confirmed histopathologically as the gold standard. Comparative analysis of the sensitivity, specificity, and accuracy based on FDG PET/CT and MSCT was conducted. Results: There were 946 lymph node groups resected during surgery from 115 patients, and 221 were confirmed to have metastasis pathologically. The sensitivity, specificity, accuracy of FDG PET/CT in detecting lymph node metastasis were 74.7%, 97.2% and 92.0%, while with MSCT they were 64.7%, 96.4%, and 89.0%, respectively. A significance difference was observed in sensitivity (p=0.030), but not the others (p>0.05). The accuracy of FDG PET/CT in detecting regional lymph node with or without metastasis were 91.9%, as compared to 89.4% for MSCT, while FDG PET/CT and MSCT values for detecting distant lymph node with or without metastasis were 94.4% and 94.7%. No significant difference was observed for either regional or distant lymph node metastasis. Additionally, for detecting para-esophageal lymph nodes metastasis, the sensitivity of FDG PET/CT was 72%, compared with 54.7% for MSCT (p=0.029). Conclusions: FDG PET/CT is more sensitive than MSCT in detecting lymph node metastasis, especially for para-esophageal lymph nodes in esophageal cancer cases, although no significant difference was observed between FDG PET/CT and MSCT in detecting both regional and distant lymph node metastasis. However, enhanced MSCT was found to be of great value in distinguishing false negative metastatic lymph nodes from FDG PET/CT. The combination of FDG PET/CT with MSCT should improve the accuracy in lymph node metastasis staging of esophageal cancer.


  1. Jiang JT, Zhang LF, Zhou B, et al (2012). Relationships of uPA and VEGF expression in esophageal cancer and microvascular density with tumorous invasion and metastasis. Asian Pac J Cancer Prev, 13, 3379-83.
  2. Aranda-Hernandez J, Cirocco M, Marcon N (2014). Treatment of dysplasia in barrett esophagus. Clin Endosc, 47, 55-64.
  3. Choi J, Kim SG, Kim JS, Jung HC, Song IS (2010). Comparison of endoscopic ultrasonograph (EUS), positron emission tomography (PET), and computed tomography (CT) in the preoperative locoregional staging of resectable esophageal cancer. Surg Endosc, 24, 1380-86.
  4. Feng JF, Huang Y, Chen QX (2013). Prognostic value of preoperative serum CA 242 in esophageal squamous cell carcinoma cases. Asian Pac J Cancer Prev, 14, 1803-6.
  5. Kato H, Kuwano H, Nakajima M, et al (2002). Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer, 94, 921-8.
  6. Kim K, Park SJ, Kim BT, et al (2001). Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography. Ann Thorac Sug, 71, 290-4.
  7. Lee S, Yoo JH, Lee SW (2012). Kikuchi disease: differentiation from tuberculous lymphadenitis based on patterns of nodal necrosis on CT. AJNR Am J Neuroradiol, 33, 135-40.
  8. Lerut T, Flamen P, Ectors N, et al (2000). Histopathologic validation of lymph node staging with FDG PET scan in cancer of the esophagus and gastroesophageal junction: A prospective study based on primary surgery with extensive lymphadenectomy. Ann Surg, 232, 743-52.
  9. Manabe O, Hattori N, Hirata K, et al (2013). Diagnostic accuracy of lymph node metastasis depends on metabolic activity of the primary lesion in thoracic squamous esophageal cancer. J Nucl Med, 54, 670-6.
  10. Li YM, Lin Q, Zhao L, et al (2014). Pre-treatment metabolic tumor volume and total lesion glycolysis are useful prognostic factors for esophageal squamous cell cancer patients. Asian Pac J Cancer Prev, 15, 1369-73.
  11. Luketich JD, Schauer PR, Meltzer CC, et al (1997). Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg, 64, 765-9.
  12. Ma JB, Chen EC, Song YP, et al (2013). Prognostic significance of 18F-fluorodeoxyglucose positron emission tomography (PET)-based parameters in neoadjuvant chemoradiation treatment of esophageal carcinoma. Asian Pac J Cancer Prev, 14, 2477-81.
  13. Mizowaki T, Nishimura Y, Shimada Y, et al (1996). Optimal size criteria of malignant lymph nodes in the treatment planning of radiotherapy for esophageal cancer:evaluation by computed tomography and magnetic resonance imaging. Int J Radiat Oncol Biol Phys, 36, 1091-98.
  14. Okada M, Murakami T, Kumano S, et al (2009). Integrated FDG-PET/CT compared with intravenous contrast-enhanced CT for evaluation of metastatic regional lymph nodes in patients with resectable early stage esophageal cancer. Ann Nucl Med, 23, 73-80.
  15. Saha S, Dehn TC (2001). Ratio of invaded to removed lymph nodes as a prognostic factor in adenocarcinoma of the distal esophagus and esophagogastric junction. Dis Esophagus, 14, 32-36.
  16. Schreurs LM, Pultrum BB, Koopmans KP, et al (2008). Better assessment of nodal metastases by PET/CT fusion compared to side-by-side PET/CT in oesophageal cancer. Anticancer Res, 28, 1867-73.
  17. Yoon YC, Lee KS, Shim YM, et al (2003). Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection prospective study. Radiology, 227, 764-70.
  18. Tanaka T, Matono S, Mori N, Shirouzu K, Fujita H (2013). T1 squamous cell carcinoma of the esophagus: long-term outcomes and prognostic factors after esophagectomy. Ann Surg Oncol, 21, 932-8.
  19. Yasuda S, Raja S, Hubner KF (1995). Application of whole-body positron emission tomography in the imaging of esophageal cancer: report of a case. Surg Today, 25, 261-4.
  20. Yen TJ, Chung CS, Wu YW, et al (2012). Comparative study between endoscopic ultrasonography and positron emission tomography-computed tomography in staging patients with esophageal cell carcinoma. Dis Esophagus, 25, 40-47.
  21. You JJ, Wong RK, Darling G, et al (2013). Clinical utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the staging of patients with potentially resectable esophageal cancer. J Thorac Oncol, 8, 1563-69.

피인용 문헌

  1. Role of PET/CT in Treatment Planning for Head and Neck Cancer Patients Undergoing Definitive Radiotherapy vol.15, pp.24, 2015,
  2. Use of Imaging for GI Cancers vol.33, pp.16, 2015,
  3. Effects and Mechanisms of Metformin on the Proliferation of Esophageal Cancer Cells In Vitro and In Vivo vol.49, pp.3, 2017,
  4. Improving CT detection sensitivity for nodal metastases in oesophageal cancer with combination of smaller size and lymph node axial ratio vol.28, pp.1, 2018,